[
  {
    "ts": null,
    "headline": "Farxiga and Jardiance pose affordability issues, says Maryland drug board",
    "summary": "The state’s independent body approved resolutions stating that both drugs present affordability challenges.",
    "url": "https://finnhub.io/api/news?id=e801b4d6b50d02879f37a253a213eaa7ef7c5f0b5ff3ddb27b5378cbed8b8753",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753918007,
      "headline": "Farxiga and Jardiance pose affordability issues, says Maryland drug board",
      "id": 136148816,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The state’s independent body approved resolutions stating that both drugs present affordability challenges.",
      "url": "https://finnhub.io/api/news?id=e801b4d6b50d02879f37a253a213eaa7ef7c5f0b5ff3ddb27b5378cbed8b8753"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk A/S (NVO) Could Lose To Eli Lilly, Warns Jim Cramer",
    "summary": "We recently published 10 Stocks That Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO) came up during the show in the context of trade discussions between the US and Europe and potential tariffs on the pharmaceutical sector. For context, Novo Nordisk A/S […]",
    "url": "https://finnhub.io/api/news?id=5eb3ebff89e810996d62aa54d37ba10a652d9552a87c6c470d6f49953039f76d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753902232,
      "headline": "Novo Nordisk A/S (NVO) Could Lose To Eli Lilly, Warns Jim Cramer",
      "id": 136148817,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks That Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO) came up during the show in the context of trade discussions between the US and Europe and potential tariffs on the pharmaceutical sector. For context, Novo Nordisk A/S […]",
      "url": "https://finnhub.io/api/news?id=5eb3ebff89e810996d62aa54d37ba10a652d9552a87c6c470d6f49953039f76d"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health Corporation (CVS) Is A Key Part Of Weight Loss Drug Distribution, Says Jim Cramer",
    "summary": "We recently published 10 Stocks That Jim Cramer Talked About. CVS Health Corporation (NYSE:CVS) is one of the stocks Jim Cramer recently discussed. CVS Health Corporation (NYSE:CVS) is one of the largest pharmaceutical retailers in America. The shares have gained 36% year-to-date as the firm has enjoyed tailwinds from the struggles of its rival Walgreens. […]",
    "url": "https://finnhub.io/api/news?id=aef2f83a67b0501ebfcadc4963b37f8e5623cf74c11cedfaaf6c33a899903752",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753902207,
      "headline": "CVS Health Corporation (CVS) Is A Key Part Of Weight Loss Drug Distribution, Says Jim Cramer",
      "id": 136147863,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks That Jim Cramer Talked About. CVS Health Corporation (NYSE:CVS) is one of the stocks Jim Cramer recently discussed. CVS Health Corporation (NYSE:CVS) is one of the largest pharmaceutical retailers in America. The shares have gained 36% year-to-date as the firm has enjoyed tailwinds from the struggles of its rival Walgreens. […]",
      "url": "https://finnhub.io/api/news?id=aef2f83a67b0501ebfcadc4963b37f8e5623cf74c11cedfaaf6c33a899903752"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): Jim Cramer’s “Bullish” On News Of Tariffs",
    "summary": "We recently published 10 Stocks That Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) is one of Cramer’s top pharmaceutical stocks. While the firm’s weight loss drugs are one reason the CNBC TV host likes it, he’s also bullish on […]",
    "url": "https://finnhub.io/api/news?id=ec5cbc07855d0332568210b79bf6655acd7aefc9b94b4a01a7e690edea34e13f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753902163,
      "headline": "Eli Lilly and Company (LLY): Jim Cramer’s “Bullish” On News Of Tariffs",
      "id": 136148819,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks That Jim Cramer Talked About. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) is one of Cramer’s top pharmaceutical stocks. While the firm’s weight loss drugs are one reason the CNBC TV host likes it, he’s also bullish on […]",
      "url": "https://finnhub.io/api/news?id=ec5cbc07855d0332568210b79bf6655acd7aefc9b94b4a01a7e690edea34e13f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Unveils Alzheimer's And CLL Trial Results With New LTZ Collaboration",
    "summary": "Eli Lilly (LLY) has been actively progressing its pharmaceutical offerings and forging new alliances, as recent product results and collaborations indicate a commitment to innovation in Alzheimer's and blood cancer treatments. The continuous advancements with Kisunla and Jaypirca, alongside partnerships like the one with LTZ Therapeutics, highlight the company’s focused push towards addressing significant medical needs. Despite these positive developments, Eli Lilly's stock saw a 1.61%...",
    "url": "https://finnhub.io/api/news?id=a709ce61ce3e7f305d93c3a0555f57171f9fa9005e9ffcd34b8ade39713452e5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753897059,
      "headline": "Eli Lilly (LLY) Unveils Alzheimer's And CLL Trial Results With New LTZ Collaboration",
      "id": 136148820,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) has been actively progressing its pharmaceutical offerings and forging new alliances, as recent product results and collaborations indicate a commitment to innovation in Alzheimer's and blood cancer treatments. The continuous advancements with Kisunla and Jaypirca, alongside partnerships like the one with LTZ Therapeutics, highlight the company’s focused push towards addressing significant medical needs. Despite these positive developments, Eli Lilly's stock saw a 1.61%...",
      "url": "https://finnhub.io/api/news?id=a709ce61ce3e7f305d93c3a0555f57171f9fa9005e9ffcd34b8ade39713452e5"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Don't Miss Buying This Dip",
    "summary": "Novo Nordisk's launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability for the new CEO. Learn more on NVO stock here.",
    "url": "https://finnhub.io/api/news?id=9a639fce98e0a7046620c7f70ad1046c5e45d289098159220b9d3709479b0cc1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753884155,
      "headline": "Novo Nordisk: Don't Miss Buying This Dip",
      "id": 136136508,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305433/image_2158305433.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk's launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability for the new CEO. Learn more on NVO stock here.",
      "url": "https://finnhub.io/api/news?id=9a639fce98e0a7046620c7f70ad1046c5e45d289098159220b9d3709479b0cc1"
    }
  },
  {
    "ts": null,
    "headline": "NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?",
    "summary": "Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.",
    "url": "https://finnhub.io/api/news?id=da24deb18b7e1f2f92263b7ebb1a9d671aa21ed4c3e6ed7c1a473891c58dfb44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753883820,
      "headline": "NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?",
      "id": 136148821,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.",
      "url": "https://finnhub.io/api/news?id=da24deb18b7e1f2f92263b7ebb1a9d671aa21ed4c3e6ed7c1a473891c58dfb44"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Got Battered. Think Twice Before Buying the Dip.",
    "summary": "Novo Nordisk is in the sick bay.  The stock had its worst day since Black Monday and Wall Street is becoming increasingly skeptical that the weight-loss drugmaker can play catch-up in an increasingly competitive market.  Analysts were lowering their expectations on the stock after  Novo  slashed its full-year outlook Tuesday citing the persistent use of copycat versions of GLP-1s—a type of gut hormone that help regulate blood sugar levels and control appetite—in the U.S., which it vowed to fight.",
    "url": "https://finnhub.io/api/news?id=44ec3a193dfd8b7a110f923452d6efcde053ac1d99f93e355814284defd08f78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753876920,
      "headline": "Novo Nordisk Stock Got Battered. Think Twice Before Buying the Dip.",
      "id": 136129637,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk is in the sick bay.  The stock had its worst day since Black Monday and Wall Street is becoming increasingly skeptical that the weight-loss drugmaker can play catch-up in an increasingly competitive market.  Analysts were lowering their expectations on the stock after  Novo  slashed its full-year outlook Tuesday citing the persistent use of copycat versions of GLP-1s—a type of gut hormone that help regulate blood sugar levels and control appetite—in the U.S., which it vowed to fight.",
      "url": "https://finnhub.io/api/news?id=44ec3a193dfd8b7a110f923452d6efcde053ac1d99f93e355814284defd08f78"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease",
    "summary": "Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) demonstrated slowing of decline, a benefit that continued to grow over three years compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI).1",
    "url": "https://finnhub.io/api/news?id=ac2a45f19059f4f05d20ccccbca7dfac37848f95153490d9ec30df2f9c421e53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753876860,
      "headline": "Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease",
      "id": 136129638,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) demonstrated slowing of decline, a benefit that continued to grow over three years compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI).1",
      "url": "https://finnhub.io/api/news?id=ac2a45f19059f4f05d20ccccbca7dfac37848f95153490d9ec30df2f9c421e53"
    }
  },
  {
    "ts": null,
    "headline": "MedaSystems Strengthens Executive Team with Appointment of Anton White as Vice President of Growth",
    "summary": "MENLO PARK, Calif., July 30, 2025--MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator‑Initiated Studies (IIS), today announced that healthcare‑technology veteran Anton White has joined the company as Vice President of Growth. White will lead global go‑to‑market strategy and execution as MedaSystems scales to meet accelerating demand from biopharmaceutical partners worldwide.",
    "url": "https://finnhub.io/api/news?id=5b321514b3e0ace3010df4e85146e897d8553ac9e116a12b2374c11f5e0373cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753869900,
      "headline": "MedaSystems Strengthens Executive Team with Appointment of Anton White as Vice President of Growth",
      "id": 136129639,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "MENLO PARK, Calif., July 30, 2025--MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator‑Initiated Studies (IIS), today announced that healthcare‑technology veteran Anton White has joined the company as Vice President of Growth. White will lead global go‑to‑market strategy and execution as MedaSystems scales to meet accelerating demand from biopharmaceutical partners worldwide.",
      "url": "https://finnhub.io/api/news?id=5b321514b3e0ace3010df4e85146e897d8553ac9e116a12b2374c11f5e0373cc"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL",
    "summary": "Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).",
    "url": "https://finnhub.io/api/news?id=012aa4ed868c1c7e047e64764fd3f20c7b42cabe04677cda546a6c7eb053b1bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753868462,
      "headline": "Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL",
      "id": 136129640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).",
      "url": "https://finnhub.io/api/news?id=012aa4ed868c1c7e047e64764fd3f20c7b42cabe04677cda546a6c7eb053b1bb"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?",
    "summary": "Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and future outlook.",
    "url": "https://finnhub.io/api/news?id=75ac7a5285b03e5acc96ad9b248fb39176f2501a7a3250d49e57f876761a4824",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753866000,
      "headline": "Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?",
      "id": 136129244,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2191750927/image_2191750927.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and future outlook.",
      "url": "https://finnhub.io/api/news?id=75ac7a5285b03e5acc96ad9b248fb39176f2501a7a3250d49e57f876761a4824"
    }
  },
  {
    "ts": null,
    "headline": "IXJ: A Bet On Global Healthcare Recovery",
    "summary": "IXJ offers global healthcare exposure, capturing demographic shifts and innovation trends beyond U.S.-centric ETFs. Read why IXJ ETF is a Buy.",
    "url": "https://finnhub.io/api/news?id=efbb41a862d9a020aa33084c6f7cb09c8955e6659667bd377b0249cad00c608b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753839218,
      "headline": "IXJ: A Bet On Global Healthcare Recovery",
      "id": 136127584,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/174965679/image_174965679.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "IXJ offers global healthcare exposure, capturing demographic shifts and innovation trends beyond U.S.-centric ETFs. Read why IXJ ETF is a Buy.",
      "url": "https://finnhub.io/api/news?id=efbb41a862d9a020aa33084c6f7cb09c8955e6659667bd377b0249cad00c608b"
    }
  }
]